dronabinol (Marinol)
Jump to navigation
Jump to search
Introduction
Tradename: Marinol. DEA-controlled substance: class 3. (delta-9-tetrahydrocannabinol)
Indications
- control of nausea/vomiting associated with cancer chemotherapy
- treatment of anorexia in patients with AIDS
- treatment of Alzheimer's disease ?[5]
Dosage
- chemotherapy-induced nausea:
- 5 mg/m1 1-3 hours prior to chemotherapy, the
- 5 mg/m2 every 2-4 hours after chemotherapy up to 6 doses/day
- maximum dose: 15 mg/m2: increase in 2.5 mg/m2 increments
- AIDS anorexia: 2.5 mg PO BID
- elderly: start 2.5 mg QHS
Tabs: 2.5, 5, 10 mg.
Pharmacokinetics
- metabolized in liver
- primary psychoactive metabolite is 11-OH-THC
- primary urinary metabolite is 11-nor-delta-9-tetrahydro- cannabinol-9-carxoxylic acid
elimination via liver
1/2life = 25-36 hours
protein binding = 94-99 %
Adverse effects
- common (> 10%)
- drowsiness, dizziness, detachment, anxiety, difficulty concentrating, mood disorder
- less common (1-10%)
- uncommon (< 1%)
- some question about lowering of seizure threshold[4]
Drug interactions
Laboratory
Mechanism of action
- central sympathomimetic activity[6]
- putative cannabinoid receptor agonist
More general terms
Component of
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
- ↑ 4.0 4.1 Prescriber's Letter 12(6):32 2005 New Drug: Sativex (Delta-9-tetrahydrocannabinol and Cannabidiol) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210605&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 Associated Press Oct 6, 2006
- ↑ 6.0 6.1 HIGHLIGHTS OF PRESCRIBING INFORMATION MARINOL (dronabinol) capsules, for oral use, CIII https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf